文献速递白血病

阿西米尼或博舒替尼治疗耐药/不耐受慢性期慢性髓性白血病患者的健康相关生活质量:3期ASCEMBL试验

Health-related quality of life of patients with resistant/intolerant chronic phase chronic myeloid leukemia treated with asciminib or bosutinib in the phase 3 ASCEMBL trial.
PubMed 文献 · Leukemia · 2023-04-14

ASCEMBL是一项开放标签、随机3期研究,比较阿西米尼与博舒替尼在既往接受≥2种酪氨酸激酶抑制剂治疗的慢性期慢性髓性白血病(CML-CP)患者中的疗效与安全性。患者完成MDASI-CML、EQ-5D-5L、PGIC-CML和WPAI-CML问卷评估健康相关生活质量(HRQOL)。阿西米尼治疗48周内CML症状与HRQOL保持稳定,CML症状严重程度总体呈下降趋势(尤其疲乏),HRQOL改善;博舒替尼组腹泻严重程度较阿西米尼组出现有临床意义的增加。

要点

  • 阿西米尼治疗48周内CML症状与HRQOL保持稳定,疲乏严重程度呈下降趋势。
  • 博舒替尼组腹泻严重程度较阿西米尼组出现有临床意义的增加。
  • 数据补充了后线治疗中患者视角与治疗对HRQOL影响的信息。

核心结论

  • 阿西米尼治疗48周内患者CML症状和HRQOL保持稳定,CML症状严重程度总体呈下降趋势(尤其疲乏),HRQOL改善。
  • 博舒替尼组腹泻严重程度较阿西米尼组出现有临床意义的增加。

研究设计与样本

  • ASCEMBL为开放标签、随机3期研究。
  • 研究对象为既往接受≥2种酪氨酸激酶抑制剂治疗的慢性期慢性髓性白血病(CML-CP)患者。
  • 患者完成MDASI-CML、EQ-5D-5L、PGIC-CML和WPAI-CML问卷评估HRQOL。

主要发现

  • 阿西米尼治疗48周内CML症状和HRQOL保持稳定。
  • 阿西米尼组CML症状严重程度总体呈下降趋势,尤其疲乏。
  • 阿西米尼组HRQOL改善。
  • 博舒替尼组腹泻严重程度较阿西米尼组出现有临床意义的增加。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In ASCEMBL, an open-label, randomized Phase 3 study, asciminib demonstrated superior efficacy and better safety profile compared with bosutinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) previously treated with ≥2 tyrosine kinase inhibitors. Health-related quality of life (HRQOL) reported by patients is key to understanding the benefit and impact of treatment on patients' lives, and is becoming increasingly important as the life expectancy of CML-CP patients increases and patients require long-term treatment. In ASCEMBL, patients completed questionnaires to assess CML symptoms and interference with daily life (M.D. Anderson Symptom Inventory - CML [MDASI-CML]), general HRQOL (five-level EQ-5D [EQ-5D-5L], Patient Global Impression of Change - CML [PGIC-CML]), and impact of CML on working life and activity (Work Productivity and Activity Impairment questionnaire - CML [WPAI-CML]). Patients' CML symptoms and HRQOL remained stable during 48 weeks of treatment with asciminib, with a general trend for decreased CML symptom severity, particularly for fatigue, and improvement in HRQOL. A clinically meaningful increase in diarrhea severity was observed in patients treated with bosutinib compared to asciminib. These data provide better understanding of the patient perspective and treatment impact on HRQOL in a later-line setting, where little information has been published to date.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Réa D, Boquimpani C, Mauro MJ, et al. Health-related quality of life of patients with resistant/intolerant chronic phase chronic myeloid leukemia treated with asciminib or bosutinib in the phase 3 ASCEMBL trial. Leukemia. 2023. PMID: 37069326. doi:10.1038/s41375-023-01888-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。